A combination therapy of doxorubicin with pirfenidone, an antifibrotic agent and a TGFβ antagonist has great potential for the therapy of triple negative breast cancer targeting tumor-stroma interactions [38]. The gene discussed is TGFB1; the disease is triple-negative breast carcinoma.